Asia Pacific Multiomics Market Size, Share & Trends Analysis Report By Omics Type (Genomics, Transcriptomics, Proteomics, Metabolomics), By Application (Drug Discovery and Development, Precision Medicine and Personalized Therapy, Biomarker Identification, Clinical Diagnostics), By Country (China, South Korea, Japan, India, Australia, Singapore, Taiwan, Southeast Asia) and Forecast, 2026-2034

Asia Pacific Multiomics Market Trends

Single-Cell, AI and High-Throughput Integration Reshape Research Workflows

Single-cell workflows are moving toward substantially larger experimental volumes. In 2026, Parse Biosciences introduced Evercode Whole Transcriptome v4 supporting up to 5 million cells and 384 samples per run. Illumina has also developed Perturb-seq configurations supporting 10,000, 100,000 and 1 million cells per sample, with genome-scale experiments exceeding 10,000 guide RNAs.

Technology demand is shifting from isolated assays toward integrated sequencing, bioinformatics and AI-assisted interpretation. Parse technology was already used across more than 3,000 laboratories in 40+ countries when QIAGEN announced its acquisition, while scalable chemistries increasingly target millions or billions of cells. This transition strengthens demand from oncology, immunology, drug discovery and translational research laboratories.

Asia Pacific Multiomics Market Drivers

Expansion of High-Throughput Sequencing and Precision Biology

Falling workflow barriers and higher experimental throughput are accelerating adoption. New single-cell systems can process up to 5 million cells across 384 samples, while high-throughput sample-preparation platforms can purify 192 DNA or RNA samples per run. QIAGEN expects Parse to contribute approximately USD 40 million in 2026 sales, while its broader growth pillars generated USD 1.49 billion in 2025 after expanding 8%, demonstrating commercial momentum around scalable molecular-analysis infrastructure.

Asia Pacific Multiomics Market Restraints

High Workflow Costs and Complex Data Integration Limit Broad Deployment

Single-cell sequencing adoption continues to face high reagent costs, specialized-equipment requirements and accessibility constraints. Experiments now ranging from 10,000 to 1 million cells per sample generate computationally intensive datasets, while workflows integrating 3, 4 or more molecular layers require additional storage, normalization and specialist bioinformatics. These requirements particularly constrain smaller laboratories with limited capital budgets and computational personnel.

Asia Pacific Multiomics Market Opportunities

AI-Enabled Single-Cell Biology Opens Large-Scale Translational Applications

AI-supported drug discovery creates opportunities for platforms capable of generating exceptionally large biological datasets. Parse workflows are designed for millions to billions of cells, and QIAGEN acquired the company for approximately USD 225 million upfront plus up to USD 55 million in milestones. The acquired business is expected to contribute around USD 40 million during 2026, with subsequent double-digit expansion anticipated.

Challenges in Asia Pacific Multiomics Market

Standardization Across Heterogeneous Molecular Datasets Remains Difficult

Combining DNA, RNA, proteins and metabolites creates substantial normalization and reproducibility challenges. Modern platforms can analyze 384 samples and 5 million cells in one run, while Perturb-seq workflows can extend beyond 10,000 gRNAs per experiment. Such scale intensifies requirements for interoperable pipelines, cloud computing, quality-control standards and trained computational biologists.

Asia Pacific Multiomics Market Segmentation

The industry is segmented by omics type, application, technology, offering and end user. Among quantified omics categories, genomics accounts for approximately 34.1% of 2026 revenue, transcriptomics 19.0% and proteomics 15.0%.

By Omics Type

Genomics leads with USD 209.14 million in 2026 and is forecast to reach USD 713.57 million by 2034 at 16.58% CAGR, supported by sequencing-led research and genomic integration with other molecular datasets.

Epigenomics is the fastest-growing category at 16.63% CAGR, expanding from USD 66.55 million in 2026 to USD 227.84 million by 2034. Transcriptomics reaches USD 397.61 million, proteomics USD 310.13 million and metabolomics USD 201.62 million by 2034.

By Application

Drug discovery and development represents a central application as pharmaceutical researchers integrate 2 or more molecular layers for target validation and mechanism-of-action studies. Precision medicine, biomarker identification and clinical diagnostics are increasingly connected to single-cell workflows capable of evaluating millions of cells.

Precision medicine and personalized therapy are positioned for rapid adoption as oncology and immunology programs integrate genomic, transcriptomic and proteomic measurements. Other applications include agriculture and crop research, nutrigenomics, infectious-disease surveillance and systems biology.

By Technology

Next-generation sequencing remains foundational to integrated molecular analysis, supported by platforms handling experiments from thousands to millions of cells. Mass spectrometry provides complementary proteomic and metabolomic measurement, while microarrays and real-time PCR remain relevant for targeted workflows.

Single-cell analysis and integration platforms are advancing rapidly as experiments scale to 5 million cells and 384 samples per run. AI-supported bioinformatics increasingly connects NGS, mass spectrometry and other analytical outputs into unified datasets.

By Offering

Software and services are increasingly important because multi-layer datasets require normalization, interpretation, visualization and AI-assisted analytics. Instruments remain essential for sequencing and mass-spectrometry workflows, while consumables generate recurring demand across sample preparation and assay execution.

The expansion of studies involving millions of cells increases recurring reagent requirements and cloud-computing workloads. QIAGEN's acquired Parse operation is expected to generate approximately USD 40 million in 2026 sales, illustrating commercialization potential for integrated sample-to-analysis offerings.

By End User

Pharmaceutical and biotechnology companies constitute a major user group because drug discovery increasingly combines molecular datasets for target identification, biomarker development and patient stratification. Academic institutions also support high experimental volumes, while CROs provide outsourced sequencing and computational capabilities.

Hospitals, clinics and public-health agencies represent developing users as research workflows transition toward translational applications. Platforms supporting 192 samples per purification run and single-cell experiments reaching 5 million cells can improve scalability for centralized laboratories.

Asia Pacific Multiomics Market Counties Outlook

China

China generates USD 242.82 million in 2026, equivalent to 39.6% of the regional total, and is projected to reach USD 829.61 million by 2034 at 16.60% CAGR. Sequencing, pharmaceutical R&D and precision medicine form major demand centers.

South Korea

South Korea contributes 5.0% in 2026 with USD 30.78 million, increasing to USD 104.60 million by 2034 at 16.52% CAGR. Single-cell sequencing and biomedical research support laboratory throughput; Illumina introduced its PIPseq-based single-cell workflow to Korean researchers in 2025.

Japan

Japan accounts for 13.0% of 2026 revenue at USD 79.65 million and reaches USD 262.75 million by 2034, recording 16.09% CAGR. Pharmaceutical research, proteomics and translational genomics underpin adoption.

India

India contributes 18.2% with USD 111.87 million in 2026 and is forecast at USD 365.00 million by 2034, representing 15.93% CAGR. Expanding sequencing capacity and biotechnology research support broader utilization.

Australia

Australia represents 5.0% of regional revenue with USD 30.95 million in 2026, increasing to USD 103.01 million by 2034 at 16.22% CAGR. Genomics, clinical research and academic programs constitute core demand channels.

Singapore

Singapore accounts for 2.1% in 2026 at USD 12.75 million and reaches USD 44.14 million by 2034. Its 16.79% CAGR is the fastest among listed countries, supported by biomedical research and precision-health infrastructure.

Taiwan

Taiwan contributes 6.1% with USD 37.55 million in 2026 and is forecast at USD 122.85 million by 2034 at 15.97% CAGR. Genomic research, biotechnology and clinical applications support adoption.

Southeast Asia

Southeast Asia contributes 10.9% of 2026 revenue at USD 67.04 million and reaches USD 224.36 million by 2034 at 16.30% CAGR, supported by expanding research laboratories, sequencing access and infectious-disease programs.

Top players in Asia Pacific multiomics market

1. Thermo Fisher Scientific
2. Illumina
3. QIAGEN
4. Agilent Technologies
5. Bruker
6. Shimadzu Corporation
7. Becton, Dickinson and Company
8. 10x Genomics
9. BGI Group
10. Pacific Biosciences
11. Oxford Nanopore Technologies
12. Bio-Rad Laboratories
13. Danaher Corporation
14. Standard BioTools
15. Takara Bio

Top Two Companies

• Thermo Fisher Scientific: The company maintains a leading competitive position through sequencing, mass spectrometry, reagents, sample preparation and analytical software. Established vendors collectively address multiple workflow layers rather than a single assay category, strengthening cross-selling into pharmaceutical and academic laboratories. The regional competitive structure remains fragmented, and no reliable company-specific Asia-Pacific percentage is supplied in the mandatory dataset; therefore, an unsupported numeric company share is not assigned. Its positioning is strongest where laboratories require integrated instrumentation, consumables and services across 2 or more omics layers.
• Illumina: Illumina holds a prominent sequencing-centered position and has expanded into single-cell analysis through Fluent BioSciences/PIPseq technology. Its Perturb-seq architecture targets formats spanning10,000, 100,000 and 1 million cells per sample, while supporting experiments exceeding 10,000 gRNAs. No validated Asia-Pacific company-specific percentage is contained in the supplied dataset, so a numerical competitive share is not fabricated. Its position is reinforced by sequencing infrastructure, integrated single-cell workflows and expansion toward high-scale transcriptomic and CRISPR applications.

Recent Developments in the Asia Pacific Multiomics Market

• 2026: Parse Biosciences, a QIAGEN company, launched Evercode Whole Transcriptome v4, supporting up to 5 million cells and 384 samples per run.
• 2026: QIAGEN positioned Parse single-cell analysis among its strategic priorities, expecting approximately USD 40 million in 2026 sales contribution.
• 2025: QIAGEN agreed to acquire Parse Biosciences for approximately USD 225 million upfront, plus potential milestones of up to USD 55 million.
• 2025: Illumina expanded PIPseq-based single-cell workflows, including a Korean program supporting accessible scRNA-seq and multi-omic studies.
• 2025: Illumina announced Perturb-seq technology supporting configurations from 10,000 to 1 million cells per sample and genome-scale experiments above 10,000 gRNAs.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 treated as historical years. Mandatory supplied country and omics-type tables are the primary quantitative source. Country shares are calculated against the supplied USD 613.41 million 2026 regional total, while omics contributions use the supplied USD 613.94 million omics total. Secondary sources are used only for technology, competitive and development context; unsupported segment or company percentages are not fabricated.